NCT05890287View on ClinicalTrials.gov

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

May 1, 2026

Study Completion Date

October 1, 2026

Conditions
HR Positive HER2 Negative Advanced Breast Cancer
Interventions
DRUG

Chidamide

Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen

Trial Locations (1)

Unknown

RECRUITING

天津市肿瘤医院, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER